---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-000238"
form_type: "8-K"
ticker: "SCYX"
cik: "0001178253"
company_name: "SCYNEXIS INC"
filed_at: "2024-01-02T23:59:59+00:00"
generated_at: "2026-06-07T05:05:41.337722+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# SCYNEXIS amends GSK license after BREXAFEMME recall; milestone payments cut

## Summary
- Binding MOU amends March 2023 license after beta-lactam contamination risk triggered BREXAFEMME recall and clinical hold.
- Regulatory milestone cap reduced to $49M (from $70M); commercial milestone cap to $57.5M (from $115M).
- Sales milestone caps lowered to $179.5M/$169.75M/$145.5M (from $242.5M), depending on relaunch date.
- Up to $72.35M in development milestones, including $30M for MARIO study resumption after clinical hold lifted.
- GSK already paid $90M upfront and $25M development milestone; royalty rates unchanged (mid-single to mid-teen).

## SEC filing metadata
- accession: 0000950170-24-000238
- form_type: 8-K
- ticker: SCYX
- cik: 0001178253
- company_name: SCYNEXIS INC
- filed_at: 2024-01-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178253/000095017024000238/0000950170-24-000238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178253/000095017024000238/scyx-20231226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-000238
- JSON: https://secwatch.observer/filing/0000950170-24-000238.json
- Plain text: https://secwatch.observer/filing/0000950170-24-000238.txt

## Key facts
- Material Agreements
  SCYNEXIS INC amended Binding Memorandum of Understanding for Amendment to License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited (effective 2023-12-26).
  - Action: amendment
  - Agreement: license
  - Counterparty: GlaxoSmithKline Intellectual Property (No. 3) Limited
  - Effective: 2023-12-26
  source text: On December 26, 2023, SCYNEXIS, Inc. (“SCYNEXIS”) and GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”) entered into a binding memorandum of understanding (“Binding MOU”) for amendment to the exclusive license agreement between SCYNEXIS and GSK, dated March 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178253/000095017024000238/0000950170-24-000238-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.